AR088580A1 - Metodos y composiciones para tratar el virus de la hepatitis c - Google Patents

Metodos y composiciones para tratar el virus de la hepatitis c

Info

Publication number
AR088580A1
AR088580A1 ARP120104057A ARP120104057A AR088580A1 AR 088580 A1 AR088580 A1 AR 088580A1 AR P120104057 A ARP120104057 A AR P120104057A AR P120104057 A ARP120104057 A AR P120104057A AR 088580 A1 AR088580 A1 AR 088580A1
Authority
AR
Argentina
Prior art keywords
effective amount
virus
subject
ribavirin
compositions
Prior art date
Application number
ARP120104057A
Other languages
English (en)
Original Assignee
Gilead Pharmasset Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2012/055621 external-priority patent/WO2013040492A2/en
Application filed by Gilead Pharmasset Llc filed Critical Gilead Pharmasset Llc
Publication of AR088580A1 publication Critical patent/AR088580A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Abstract

Se describe en la presente un método para tratar un sujeto infectado por el virus de la hepatitis C. Dicho método comprende administrarle al sujeto una cantidad eficaz de GS-7977 y una cantidad eficaz de ribavirina durante un período de tiempo. En un aspecto, el método comprende la administración al sujeto de un régimen de tratamiento libre de interferón que comprende una cantidad eficaz de GS7977 y una cantidad eficaz de ribavirina. En un aspecto particular, el método es suficiente para producir una cantidad no detectable de ARN del VHC en el sujeto durante al menos 12 semanas luego de la finalización del período de tiempo. También se describe en la presente una composición útil para el tratamiento de la infección por virus de la hepatitis C, dicha composición comprende una cantidad eficaz de GS-7977 y una cantidad eficaz de ribavirina.
ARP120104057A 2011-10-31 2012-10-30 Metodos y composiciones para tratar el virus de la hepatitis c AR088580A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161553481P 2011-10-31 2011-10-31
US201161564500P 2011-11-29 2011-11-29
PCT/US2012/055621 WO2013040492A2 (en) 2011-09-16 2012-09-14 Methods for treating hcv
US201261707459P 2012-09-28 2012-09-28

Publications (1)

Publication Number Publication Date
AR088580A1 true AR088580A1 (es) 2014-06-18

Family

ID=48173020

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120104057A AR088580A1 (es) 2011-10-31 2012-10-30 Metodos y composiciones para tratar el virus de la hepatitis c

Country Status (10)

Country Link
EP (1) EP2776024A1 (es)
JP (1) JP2014532657A (es)
CN (1) CN104244947A (es)
AR (1) AR088580A1 (es)
AU (1) AU2012332827A1 (es)
BR (1) BR112014010295A2 (es)
CA (1) CA2853495A1 (es)
TW (1) TW201318627A (es)
UY (1) UY34420A (es)
WO (1) WO2013066748A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2709613B2 (en) 2011-09-16 2020-08-12 Gilead Pharmasset LLC Methods for treating hcv
WO2014120981A1 (en) 2013-01-31 2014-08-07 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
WO2015197518A1 (en) * 2014-06-23 2015-12-30 Sanovel Ilac Sanayi Ve Ticaret A.S. Pharmaceutical combinations of sofosbuvir and ribavirin
US20170128482A1 (en) * 2014-06-23 2017-05-11 Sanovel Ilac Sanayi Ve Ticaret A.S. Modified release pharmaceutical compositions of sofosbuvir and ribavirin
EP2959888A1 (en) * 2014-06-23 2015-12-30 Sanovel Ilac Sanayi ve Ticaret A.S. A novel pharmaceutical composition of sofosbuvir and ribavirin
CA2972259A1 (en) 2014-12-26 2016-06-30 Emory University N4-hydroxycytidine and derivatives and anti-viral uses related thereto
CZ2015443A3 (cs) * 2015-06-26 2017-01-04 Zentiva, K.S. Farmaceutická formulace sofosbuviru
CN106109538A (zh) * 2016-07-29 2016-11-16 桂林淮安天然保健品开发有限公司 治疗丙肝的药物组合物
KR102626210B1 (ko) 2017-12-07 2024-01-18 에모리 유니버시티 N4-하이드록시사이티딘 및 유도체 및 이와 관련된 항-바이러스 용도

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
CA2699280A1 (en) 2007-09-14 2009-03-26 Schering Corporation Method of treating hepatitis c patients
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI576352B (zh) 2009-05-20 2017-04-01 基利法瑪席特有限責任公司 核苷磷醯胺
US20120107278A1 (en) 2010-10-29 2012-05-03 Pharmasset, Inc. Abbreviated hcv therapy for hcv infected patients with il28b c/c genotype
JP2014510531A (ja) * 2011-03-31 2014-05-01 エフ．ホフマン−ラ ロシュ アーゲー Ｈｃｖ治療法の選択

Also Published As

Publication number Publication date
EP2776024A1 (en) 2014-09-17
UY34420A (es) 2013-05-31
CA2853495A1 (en) 2013-05-10
JP2014532657A (ja) 2014-12-08
WO2013066748A1 (en) 2013-05-10
TW201318627A (zh) 2013-05-16
AU2012332827A1 (en) 2014-05-15
CN104244947A (zh) 2014-12-24
BR112014010295A2 (pt) 2017-04-18

Similar Documents

Publication Publication Date Title
ECSP14005678A (es) Composiciones y métodos para tratar el virus de la hepatitis c
AR088580A1 (es) Metodos y composiciones para tratar el virus de la hepatitis c
CL2017002230A1 (es) Tratamiento combinado con un agonista de tlr7 y un inhibidor del ensamblaje de la cápsida del vhb.
UY37581A (es) Compuestos para el tratamiento de la infección por virus de la hepatitis b
BR112012014729A2 (pt) terapia combinada contra hcv
ECSP14013315A (es) Inhibidores de aplicación viral
AR076570A1 (es) Moleculas de union humanas capaces de neutralizar el virus de la influenza h3n2 y usos de las mismas
AR084237A1 (es) Metodos para tratar virus de hepatitis c (hcv), composicion
ECSP12012067A (es) Inhibidores del virus de la hepatitis c
BR112018009009A8 (pt) terapia combinada de um inibidor de formação de capsídeo hbv e um interferon
GT201500046A (es) Mètodos para el tratamiento de infecciones de hepatitis b y hepatitis d
UY33897A (es) Inhibidores del virus de la hepatitis c
BR112013026345A2 (pt) composto, composição farmacêutica, uso de um composto, e, método para tratar um paciente infectado com hcv
ECSP12011610A (es) Inhibidores de la replicación de los virus de la gripe
EA201100390A1 (ru) Соединения для лечения гепатита с
CO6321290A2 (es) Nuevos inhibidores macrociclicos basados en pirrolidinilo de la replicacion de virus de la hepatitis c
MX2012004032A (es) Compuestos para el tratamiento de hepatitis c.
CO6592102A2 (es) Compuestos de sililo triciclicos fusionados y metodos de uso de los mismos para el tratamiento de enfermedades virales
AR068363A1 (es) Reduccion de infecciones concomitantes en cerdos mediante el uso de antigeno pcv2
TN2012000135A1 (en) Cyclic peptide inhibitors of hepatitis c virus replication
BR112019004560A2 (pt) tratamento combinado com agonista de tlr7 e um inibidor de formação de capsídeo de hbv
EA201300135A1 (ru) Комбинированная фармацевтическая композиция и способы лечения и профилактики инфекционных заболеваний
UY34066A (es) Inhibidores del virus de la hepatitis c
AR108829A1 (es) Vacuna contra virus de bronquitis infecciosa
ECSP21087299A (es) Composiciones y métodos para tratar el virus de la hepatitis c

Legal Events

Date Code Title Description
FA Abandonment or withdrawal